Ficerafusp alfa + Pembrolizumab
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck
Trial Timeline
Apr 1, 2026 → Apr 30, 2030
NCT ID
NCT07465276About Ficerafusp alfa + Pembrolizumab
Ficerafusp alfa + Pembrolizumab is a phase 2 stage product being developed by Bicara Therapeutics for Head and Neck Squamous Cell Carcinoma (HNSCC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07465276. Target conditions include Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck.
What happened to similar drugs?
11 of 20 similar drugs in Head and Neck Squamous Cell Carcinoma (HNSCC) were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07465276 | Phase 2 | Recruiting |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma (HNSCC)